Process for the preparation of a PDE4 inhibitor

Patent metadata

Field	Value
Publication number	US-9434691-B2
Application number	US-201414516976-A
Country	US
Kind code	B2
Filing date	Oct 17, 2014
Priority date	Oct 22, 2013
Publication date	Sep 6, 2016
Grant date	Sep 6, 2016

Abstract

The present invention relates to a process for the preparation of compounds endowed with phosphodiesterase (PDE4) inhibitory activity having formula (I). The invention also relates to the process for the isolation by crystallization of the compound (I) and to its use for the preparation of pharmaceutical compositions for inhalation in combination with suitable carriers or vehicles. The present invention also relates to solvates and crystal forms of a compound of formula (I). The synthesized product is suitable for use in pharmaceutical applications for instance in the treatment of respiratory diseases.

First claim

The invention claimed is:

1. A process for preparing a compound of formula (I):

wherein n is 0 or 1, which process comprises:
(a) reacting a compound of formula (II):

wherein n is 0 or 1, with a compound of formula (III):

wherein X is —NHSO 2 Me or —NO 2 and Z is —OH, chlorine, bromine, linear or branched (C 1 -C 6 )alkoxy, aryloxy, arylalkoxy, (C 1 -C 6 )alkylcarbonyloxy, arylcarbonyloxy, or aryl(C 1 -C 6 )alkylcarbonyloxy, to obtain a compound of formula (I) wherein n is 0 or 1 or a compound of formula (IV):

wherein n has the above reported meanings and X is —NO 2 ; and,

when a compound of formula (IV) is obtained in step (a):
(b) reducing said compound of formula (IV) to obtain a compound of formula (V):

wherein n is 0 or 1, and reacting said compound of formula (V) with methanesulfonyl halide to obtain a compound of formula (I) wherein n has the above reported meanings;
and wherein said compound of formula (II) is obtained according to any one of the alternative steps (c1) or (c2):
(c1) oxidizing a compound of formula (VI):

wherein n is 0 or 1 to obtain a compound of formula (VII):

wherein n is 0 or 1, and subsequently enantioselectively reducing said compound of formula (VII) to obtain a compound of formula (II) wherein n has the above reported meanings; or
(c2) chromatographically separating a compound of formula (VI) wherein n is 0 or 1, to obtain said compound of formula (II) and a compound of formula (VIII):

wherein n has the above reported meanings;
and optionally oxidizing said compound of formula (VIII) to a corresponding compound of formula (VII) which can may optionally subsequently reduced to said compound of formula (VI) wherein n is 0 or 1 and optionally subjected to said chromatographic separating;
and wherein all of said compounds of formula (I), (II), (IV), (V), (VI), (VII), or (VIII) wherein n is 1 can be obtained by oxidizing the corresponding compounds wherein n is 0.

2. A process according to claim 1 , wherein in said compound of formula (III), X is —NHSO 2 Me.

3. A process according to claim 1 , which comprises (a) reacting said compound of formula (II) with a compound of formula (III) wherein X is —NO 2 to obtain a compound of formula (IV) and (b) reducing said compound of formula (IV) to said compound of formula (V), and reacting said compound of formula (V) with a methanesulfonyl halide to obtain said compound of formula (I).

4. A process according to claim 1 , wherein said compound of formula (II) is obtained by (c1) oxidizing said compound of formula (VI) to said compound of formula (VII) and enantioselectively reducing said compound of formula (VII) to said compound of formula (II).

5. A process according to claim 1 , wherein said compound of formula (II) is obtained by (c2) chromatographically separating said compound of formula (VI) to obtain said compound of formula (II) and said compound of formula (VIII).

6. A process according to claim 1 , which comprises oxidizing said compound of formula (I) wherein n is 0.

7. A process according to claim 1 , which comprises reacting a compound of formula (II) with a compound of formula (III) wherein Z is —OH in the presence of a coupling reagent selected from the group consisting of DCC, CDI, HATU, HBTU, TBTU, DMTMM, COMU, EDCI, with or without HOBt, with or without an organic base selected from the group consisting of TEA, DIPEA, NMM, DBU, DBO, pyridine and DMAP, in a solvent selected from the group consisting of dimethyl sulfoxide, sulfolane, dimethyl formamide, dimethyl acetamide, N-methyl pyrrolidone, toluene, benzene, xylene, acetone, isopropyl ketone, methyl ethyl ketone, methyl isobutyl ketone, THF, dioxane, 2-methoxyethyl ether, diethyl ether, isopropyl ether, t-butyl methyl ether, ethyl acetate, isopropyl acetate, acetonitrile, dichloromethane, chloroform, chlorobenzene, and a mixture thereof.

8. A process according to claim 1 , wherein (a) said reacting is conducted in the presence of CDI and DBU in ethyl acetate.

9. A process according to claim 1 , wherein (a) said reacting is conducted in the presence of EDCI and DMAP in DMF.

10. A process according to claim 1 , wherein (b) said reducing is carried out with a reducing agent selected from the group consisting of hydrogen, cyclohexadiene, ammonium formate, formic acid, iron, tin dichloride, tin, nickel chloride, nickel, lithium aluminium hydride, sodium aluminium hydride, lithium borohydride, sodium borohydride, potassium borohydride, and sodium hydrosulfite.

11. A process according to claim 10 , wherein said reducing agent is selected from the group consisting of hydrogen, cyclohexadiene, ammonium formate and formic acid, and (b) said reducing is carried out in presence of a palladium- platinum- or nickel-based catalyst, or a catalyst selected from the group consisting of palladium on carbon, palladium sulfided on carbon, palladium on barium sulfate, palladium on calcium carbonate, and platinum on carbon.

12. A process according to claim 10 , wherein said reducing agent is formic acid, and (b) said reducing is carried out in presence of ammonia or an amine, in a solvent selected from the group consisting of water, methanol, ethanol, isopropanol, n-butanol, t-butanol, dimethyl formamide, dimethyl acetamide, N-methyl pyrrolidone, toluene, benzene, xylene, THF, dioxane, 2-methoxyethyl ether, diethyl ether, isopropyl ether, t-butyl methyl ether, ethyl acetate, isopropyl acetate, acetonitrile, and a mixture thereof.

13. A process according to claim 10 , wherein (b) said reducing is carried out with hydrogen with palladium 5% on activated carbon powder, Type A103038, sulfided in ethyl acetate.

14. A process according to claim 1 , wherein said reacting of said compound of formula (V) with methanesulfonyl halide is carried out in the presence of one or more solvents selected from the group consisting of toluene, benzene, xylene, tetrahydrofuran, dioxane, 2-methoxyethyl ether, diethyl ether, isopropyl ether, t-buthylmethyl ether, ethyl acetate, isopropyl acetate, acetonitrile, dichloromethane, chloroform, chlorobenzene, and a mixture thereof and a base selected from the group consisting of sodium hydroxide, sodium carbonate, sodium bicarbonate, sodium hydride, potassium hydroxide, potassium carbonate, potassium bicarbonate, lithium hydroxide, lithium carbonate, cesium hydroxide, cesium carbonate, cesium bicarbonate, TEA, DIPEA, NMM, DBO, pyridine, and DMAP;
or said reacting of said compound of formula (V) with methanesulfonyl halide is carried out in the presence of excess pyridine without any other solvent.

15. A process according to claim 1 , wherein said oxidizing said compound of formula (VI) to said compound of formula (VII) is carried out in the presence o

Assignees

• Chiesi Farm Spa

Inventors

• Falchi Alessandro
• Lutero Emilio
• Ferrari Emanuele
• Pivetti Fausto
• Bussolati Rocco
• Mariani Edoardo
• Vecchi Orsola
• Bappert Erhard
• Ventrici Caterina

Classifications

• A61K9/007

  Pulmonary tract; Aromatherapy · CPC title

• C07B2200/13

  Crystalline forms, e.g. polymorphs · CPC title

• A61K31/44 Primary

  Non condensed pyridines; Hydrogenated derivatives thereof · CPC title

• C07D213/61 Primary

  Halogen atoms or nitro radicals · CPC title

• A61K9/0073

  Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy; (nasal sprays A61K9/0043; inhalation of vapours of volatile or heated drugs, e.g. essential oils or nicotine, A61K9/007; devices A61M) · CPC title